Background: Cost-effectiveness is an increasingly important factor in the choice of a test or therapy.
Introduction
Clinical assessment of an individual with suspected stable coronary artery disease (CAD) is usually complemented by noninvasive tests such as the ergometric test (ET), myocardial perfusion scintigraphy (MPS), or stress echocardiography (StressEcho). Cardiac computed tomography angiography (CCTA) has broadened the options for the assessment of CAD patients and is a potentially beneficial alternative for individuals with an intermediate or a low pretest likelihood of disease (PLD) 1 . However, the generalized adoption of new techniques that, although appealing, may entail additional costs and no added value, should be considered carefully with regard to the increasing economic pressure to which healthcare systems are exposed. Therefore, it is important to determine the cost-effectiveness of diagnostic strategies routinely used for the diagnosis of stable CAD and identify patients for whom CCTA is a cost-effective alternative.
Methods
The cost-effectiveness of seven diagnostic strategies was assessed: (1) ET followed by MPS in positive or inconclusive cases, (2) ET followed by 64-detector CCTA in positive or inconclusive cases, (3) MPS (as first option), (4) StressEcho with dobutamine (as first option), (5) CCTA (as first option), (6) calcium scoring (CaSc) followed by CCTA (CACS-CCTA) when CaSc > 0, and (7) invasive coronary angiography (CATH) as the first and only test. All considered strategies presuppose the end of the diagnostic procedures when a test is negative and a confirmation CATH when the last test of the noninvasive strategy is positive or inconclusive. In addition, an eight alternative was assessed in individuals with a PLD of 10%, which involved not performing any complementary diagnostic tests and assuming the absence of obstructive CAD. A decision-making tree analysis was performed according to the method described by Patterson et al 2, 3 to assess the cost-effectiveness of each strategy according to PLD. In this method, hypothetical cohorts of patients with a certain PLD are subjected to each of the diagnostic strategies. Then, Bayesian inference is used to estimate the cost and effectiveness of each strategy according to the test characteristics. Sensitivity, specificity, and the rate of nondiagnostic tests were gathered from meta-analysis, clinical recommendations, and published series ( Table 1 ). The rate of nondiagnostic ET and StressEcho tests was calculated as the mean percentage of patients who fail to reach the target heart rate. MPS was always considered to be diagnostic, and its accuracy was considered independent of the stress method used. In addition, CCTA tests were always considered diagnostic since the meta-analysis on its accuracy was performed on an intention-to-diagnose basis, assuming that all nondiagnostic tests would be false-positive, thereby decreasing the specificity of the test 4 . The sensitivity and specificity of CaSc > 0 for the diagnosis of obstructive CAD were obtained through combined analysis of the results of two international multicenter clinical trials 5, 6 . We assumed that CATH tests would always be diagnostic, with a sensitivity and specificity of 100%.
Comparison of cost-effectiveness
The cost-effectiveness of each strategy was defined as the cost per correct diagnosis (inclusion or exclusion of obstructive CAD) in a symptomatic patient. According to this definition, a lower cost value per correct diagnosis translates into better cost-effectiveness. Comparison between the diagnostic strategies was made from the society's perspective (i.e., including all costs, regardless of the payer) 14 . To compare the incremental cost-effectiveness of each option with that of all the other alternatives, the diagnostic strategies were ranked in increasing order of cost and those outperformed by complete dominance (simultaneously more expensive and less effective) and incomplete dominance (less effective with a higher incremental cost-effectiveness ratio; ICER) were excluded. ICERs (added cost per additional correct diagnosis) were calculated for each strategy relative to the previous less expensive strategy.
Definition of cost
The cost of a diagnostic strategy includes direct and indirect costs. Direct cost was considered as the cost of the examinations performed for patients in each cohort, using the current Tabela de Preços do Serviço Nacional de Saúde (price list of the National Health Service), which was defined by the Ordinance 839-A/2009 of July 31, 2009, as a reference 15 . The price of cardiac CCTA was defined as the sum of the values of CCTA, intravenous contrast supplement, and post-processing (Table 2 ). In the CaSc-CCTA strategy, a cost of € 80.00 was assumed (identical to that of noncontrast chest CT) 15 for patients who only underwent CaSc, while a cost of € 207.10 was assumed for those who also underwent CCTA. The following indirect costs were included.
1. Cost associated with incidental findings during CaSc and cardiac CCTA. We assumed that 7% of these tests would exhibit incidental extracardiac findings of uncertain clinical significance, which would require direct investigation 16 , usually to assess lung nodules. We assumed that these cases would require noncontrast chest CT a few months later 17 at an additional cost of € 80.00 15 .
2. Cost associated with complications caused by diagnostic CATH. We assumed that the rate of major iatrogenic adverse cardiovascular events (death, myocardial infarction, or stroke) was 0.05% 18 , while that of vascular access-related complications that required transfusion or surgery was 0.4% (for a rate of 80% for radial access use) 19 . With regard to major cardiovascular events, we considered acute myocardial infarction to be a typical complication 3, 20 and estimated its cost by adding the cost for a homogeneous diagnostic group (HDG) of patients with nonfatal myocardial infarction without major complications (€3,671.53) 15 to the cost of 1 month of temporary incapacity to work, for a gross domestic product (GDP) per capita of €16,100, assuming that half of the population assessed for suspected CAD was active. The mean cost of an iatrogenic major cardiovascular event thus estimated was € 4,342. The mean cost of a vascular access complication requiring transfusion or surgery was estimated to be €1,500 (expert opinion).
3. Cost of false-negative tests. The potential cost of false-negative tests includes the cost of repeat tests for CAD diagnosis, other examinations for the differential diagnosis of chest pain, worse quality of life, and added risk for cardiovascular events due to the non-prescription of adequate medical therapy. These costs are particularly difficult to evaluate. Previous studies have used various methods to estimate that the cost of a false-negative test is 1.4-6.7 times higher than that of a false-positive test 3, 20, 21 . Therefore, false-negative tests were allocated a cost that was three times higher than that of a false-positive test (€1.818 for each false-negative test). In the scenario where no further testing is performed assuming the absence of CAD (a hypothesis considered for patients with PLD of 10%), the costs of false-negatives were the only ones taken into account.
We did not include the cost of complications caused by noninvasive tests in the model because serious complications resulting from these tests are very rare and would only marginally increase costs. In addition, the cost associated with potential exposure to ionizing radiation was not included because this was a short-term cost-effectiveness model; furthermore, there is great uncertainty about the effects of radiation doses used in these tests 22 .
Sensitivity analysis
To assess the extent to which the results obtained depended on some of the variables under study, several sensitivity analyses were performed. Calculations were repeated using new assumptions such as decreasing the sensitivity and specificity values for cardiac CCTA to 96% and 81%, respectively (lower limits of 95% confidence intervals in the meta-analysis of 53 studies) 4 , decreasing the cost of MPS to €207.10 (equating the cost of MPS with that of CCTA), decreasing the rate of inconclusive StressEcho tests to 5%, and assuming zero cost for false-negative tests. Figure 1 shows the cost-effectiveness plans for the diagnostic strategies for each scenario of PLD. In general, costs increase and the percentage of correct diagnosis decreases with increasing PLD (due to the increase in the number of false-negative tests).
Results
The composition of direct and indirect costs is shown in Table 3 (simulation of the expected results when a cohort of 100 patients with a PPT of 30% is assessed). Table 4 summarizes the results of incremental cost-effectiveness of the diagnostic strategies applied to hypothetical cohorts of 100 patients with a PLD of 10%-90%. Diagnostic strategies were presented in increasing order of cost and respective ICER for each assessed PLD. In all scenarios of PLD, the diagnostic strategies for ET-MPS, MPS, and StressEcho are dominated by alternative strategies that are less expensive and more effective. According to the cost-effectiveness criterion, choosing the best diagnostic strategy depends on the percentage of false-negative tests that one is willing to accept and on the willingness to pay for an additional correct diagnosis ( Figure 2 ). For example, for a limit of €5,000 per additional correct diagnosis, the preferred strategy would be CACS-CCTA for patients with a PLD of 10%, CCTA for those with a PLD of 20%-40%, and CATH for those with a PLD of ≥50%.
Results of sensitivity analysis
To assess the robustness of the results and the influence of several assumptions, we reformulated the model by altering some parameters such as diagnostic accuracy of CCTA, price of MPS, rate of inconclusive StressEcho tests, and cost of false-negative tests.
The decrease in sensitivity and specificity of CCTA to 96% and 81%, respectively, resulted in the increase in total cost and ICER of the strategies that include CCTA. Nevertheless, the ET-MPS, MPS, and StressEcho diagnostic strategies remained dominated, with the increasing order of cost-effectiveness shown in Table 4 being maintained for every assessed PLD.
When the cost of MPS is equated to the cost of CCTA (€ 207.10), the cost-effectiveness of the ET-MPS and MPS diagnostic strategies improves. However, these strategies remained dominated by other diagnostic methods (less expensive and more effective) for all assessed PLDs (Table 5 ).
The decrease in the rate of inconclusive StressEcho tests from 18% to 5% resulted in the improvement of its cost-effectiveness; however, this method remained dominated by other diagnostic strategies for all the assessed PLDs. When the StressEcho strategy was compared with the dominant noninvasive strategies (more cost-effective), at each level of PLD, the StressEcho strategy entailed an additional cost of €303 to €2,700 per 100 patients, along with an increase in false-negative tests from 1.1% to 5.7%.
In the model where the absence of indirect costs is assumed in patients with false-negative tests, the ET-CCTA strategy is the least expensive for all levels of PLD. However, this diagnostic procedure resulted in a significant number of false-negative tests, particularly for intermediate or high PLDs. The transition to more effective strategies becomes less expensive with the increasing prevalence of obstructive CAD (Table 6) . 
Discussion
In recent years, the need to consider the cost of clinical decisions is becoming increasingly important. Cost-effectiveness analyses allow for more efficient use of health resources and rationalize the use of new technologies, often more expensive than their alternatives. To our knowledge, this is the first assessment of the cost-effectiveness of several strategies used for the diagnosis of stable CAD in Portugal. The results of this analysis indicate that, in this country, diagnostic algorithms that include cardiac CCTA are the most cost-effective methods in symptomatic patients with suspected obstructive CAD and a PLD of ≤50%. In high-risk patients (PLD > 50%), immediate CATH appears to be the most cost-effective strategy. The model suggests that ischemia imaging techniques (MPS and StressEcho) are more expensive and less effective compared with other diagnostic strategies for all assessed PLDs. With regard to patients with a PLD of ≤50% and the conservative scenario wherein the willingness to pay for an additional correct diagnosis is €1.000, the results of incremental cost-effectiveness indicate that it is advantageous to perform an ergometric test before CCTA in patients with a lower PLD (10%), do a "rule-out" CaSc before CCTA in patients with a PLD of 20-30%, and perform up-front CCTA in patients with a PLD of 40-50%. In the more liberal scenario (willingness to pay €5.000 for an additional correct diagnosis), the preferred strategy would be SCa-CCTA for patients with a PLD of 10%, CCTA for patients with a PLD of 20%-40%, and CATH for patients with a PLD of ≥ 50%. Ultimately, the selection of a diagnostic method on the basis of cost-effectiveness criteria depends on PLD and the willingness to pay for an additional correct diagnosis. Contrary to long-term cost-effectiveness studies, in this context, there is no commonly accepted cost-effectiveness limit [for example: € 30,000/quality-adjusted life-years (QALY)] to serve as a reference for the adoption or rejection of a diagnostic strategy. However, a recent study suggested that, for a CAD prevalence of ≥30%, values of incremental cost per correct diagnosis in the short-term model are similar to those of incremental cost per QALY estimated in long-term models 23 . In a more conservative scenario, the willingness of the Portuguese society to pay for an additional correct diagnosis will be at least ≥ €1.010, which corresponds to the sum of the direct costs of MPS followed by CATH, a diagnostic strategy that is well accepted and frequently used in Portugal.
Of the scenarios assessed in the sensitivity analysis, the one in which CCTA and MPS have the same price is particularly important because this is the case in some countries. Even in this scenario, MPS remains a dominated strategy (i.e., more expensive and less effective) because it is less accurate than CCTA, particularly in terms of sensitivity. The results would only be different in a scenario (not tested) where the price of scintigraphy was identical and where scintigraphy was more accurate.
In general, these results are in line with those obtained in other countries 17, 20, [24] [25] [26] [27] [28] [29] that consider cardiac CCTA as a cost-effective method for the diagnosis or exclusion of obstructive CAD in patients with an intermediate PLD. This is probably because of a favorable combination of cost (relatively affordable) and accuracy. Better diagnostic accuracy simultaneously increases the denominator of the cost-effectiveness equation (number of correct diagnoses) and decreases the numerator, with lower indirect costs from false-negative and false-positive tests.
The interpretation of these results and analysis of their potential implications should consider several factors. First, it should be noted that the cost-effectiveness of diagnostic strategies is critically dependent on the adequate selection of patients. The calculation of PLD is a key step in selecting a cost-effective diagnostic strategy. This assessment can be easily and quickly made using validated clinical scores that were recently calibrated in European contemporary populations 30 . Second, the results of this analysis only apply to patients without known CAD. Therefore, these findings do not mean that functional tests are not useful or cost-effective in distinct contexts, namely in patients with established CAD. In the latter case, the performance of CCTA is suboptimal, and the key issues are the presence or absence of ischemia and the localization, extension, and severity of ischemia. Rather than seeing these results in terms of winners and losers, it is important to know the advantages and disadvantages of the anatomical and functional methods in different contexts. Third, it should be acknowledged that the exclusive use of anatomical methods for the diagnosis of obstructive CAD carries some risks, namely the hazard of prompting unnecessary revascularizations. However, CATH, in the assessed strategies, had a diagnostic and not necessarily therapeutic objective (as in the COURAGE study) 31 , and although both coronary angiographies (invasive or CT) essentially provide anatomical information, there is a possibility of complementing this assessment with functional information provided by coronary fraction flow reserve (FFR) measurement, which is emerging as the gold-standard and has been demonstrated to be cost-effective 32 . It is probable that, in the near future, CCTA will allow the assessment of ischemia using perfusion techniques 33 or virtual CFR measurements 34, 35 ; however, this is not yet an established procedure.
Limitations
This study has some limitations. First, it described a theoretical model, the results of which are dependent on factors such as sensitivity and specificity of various techniques that, in the real world, can be different from those reported in international studies of reference. With regard to CCTA, it should be noted that its specificity depends on PLD because of the varying prevalence of coronary calcifications. The use of intermediate values may have led to the underestimation of the cost-effectiveness of CCTA in patients with a lower PLD and overestimation in patients with a higher PLD 36 . Similarly, like in all analyses of this type, the results are only applicable to patients who are capable of undergoing any of the tests under study (i.e., able to exercise, without complete block of the left bundle branch, without severe renal impairment, and not allergic to iodinated contrast medium). We chose to exclude the costs and benefits related to periods after the diagnosis phase (such as costs of medication, revascularization, hospitalization, and possible gains in QALY) in the model because they entail greater complexity and uncertainty. However, there is evidence that the diagnosis of obstructive CAD (vs. false-negative tests) is associated with an increase of three QALYs over a period of 10 years 3 . Depending on the assumptions made, it is possible that long-term analysis produces results that are significantly different from those obtained in this analysis. In addition, to avoid a more complex analysis, not all possible diagnostic strategies were considered; we chose accessible and frequently utilized modalities and diagnostic procedures. Moreover, conclusive tests were classified as positive or negative, in a reductionist dichotomization which is inevitable in this type of analysis. Finally, cost-effectiveness should be one of the criteria considered in clinical decision-making. Other patient-related or context- 
Conclusions
The diagnostic algorithms that include cardiac CCTA are the most cost-effective in symptomatic patients with suspected stable coronary disease and a PLD of ≤50%. In these patients, depending on the PLD and the willingness to pay per correct diagnosis, CCTA may be used as a first-line test or reserved for patients with positive/inconclusive ergometric test results or CaSC > 0. In high-risk patients (PLD ≥ 60%), immediate CATH appears to be the most cost-effective strategy. For all PLDs, strategies based on ischemia tests appear to be more expensive and less effective compared with strategies based on anatomical tests.
